Cargando…
Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases
Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients’ quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785101/ https://www.ncbi.nlm.nih.gov/pubmed/36556367 http://dx.doi.org/10.3390/life12122002 |
_version_ | 1784857966810234880 |
---|---|
author | Foti, Caterina Romita, Paolo Ambrogio, Francesca Manno, Carlo Filotico, Raffaele Cassano, Nicoletta Vena, Gino Antonio De Marco, Aurora Cazzato, Gerardo Mennuni, Biagina Gisella |
author_facet | Foti, Caterina Romita, Paolo Ambrogio, Francesca Manno, Carlo Filotico, Raffaele Cassano, Nicoletta Vena, Gino Antonio De Marco, Aurora Cazzato, Gerardo Mennuni, Biagina Gisella |
author_sort | Foti, Caterina |
collection | PubMed |
description | Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients’ quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the inhibition of the interleukin (IL)-4 and IL-13 signaling. There are only a few data on the safety of dupilumab in AD patients with comorbidities, including kidney disorders. Materials and Methods: Descriptive retrospective series of three patients with chronic kidney diseases (Alport syndrome, IgA nephropathy, and hypertensive nephrosclerosis, respectively) receiving dupilumab for their concomitant severe AD. Results: Treatment with a standard dosage of dupilumab caused a relevant improvement of AD in all patients without any adverse events or worsening of renal function. In a patient with severe renal failure, the drug was effective and well tolerated without the need for any dose adjustments, also after the initiation of peritoneal dialytic treatment. Conclusion: Our case series suggests the use of dupilumab as an effective and safe treatment for AD patients suffering from renal diseases, although additional studies are required to confirm such preliminary findings. |
format | Online Article Text |
id | pubmed-9785101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97851012022-12-24 Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases Foti, Caterina Romita, Paolo Ambrogio, Francesca Manno, Carlo Filotico, Raffaele Cassano, Nicoletta Vena, Gino Antonio De Marco, Aurora Cazzato, Gerardo Mennuni, Biagina Gisella Life (Basel) Case Report Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients’ quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the inhibition of the interleukin (IL)-4 and IL-13 signaling. There are only a few data on the safety of dupilumab in AD patients with comorbidities, including kidney disorders. Materials and Methods: Descriptive retrospective series of three patients with chronic kidney diseases (Alport syndrome, IgA nephropathy, and hypertensive nephrosclerosis, respectively) receiving dupilumab for their concomitant severe AD. Results: Treatment with a standard dosage of dupilumab caused a relevant improvement of AD in all patients without any adverse events or worsening of renal function. In a patient with severe renal failure, the drug was effective and well tolerated without the need for any dose adjustments, also after the initiation of peritoneal dialytic treatment. Conclusion: Our case series suggests the use of dupilumab as an effective and safe treatment for AD patients suffering from renal diseases, although additional studies are required to confirm such preliminary findings. MDPI 2022-11-30 /pmc/articles/PMC9785101/ /pubmed/36556367 http://dx.doi.org/10.3390/life12122002 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Foti, Caterina Romita, Paolo Ambrogio, Francesca Manno, Carlo Filotico, Raffaele Cassano, Nicoletta Vena, Gino Antonio De Marco, Aurora Cazzato, Gerardo Mennuni, Biagina Gisella Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases |
title | Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases |
title_full | Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases |
title_fullStr | Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases |
title_full_unstemmed | Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases |
title_short | Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases |
title_sort | treatment of severe atopic dermatitis with dupilumab in three patients with renal diseases |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785101/ https://www.ncbi.nlm.nih.gov/pubmed/36556367 http://dx.doi.org/10.3390/life12122002 |
work_keys_str_mv | AT foticaterina treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases AT romitapaolo treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases AT ambrogiofrancesca treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases AT mannocarlo treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases AT filoticoraffaele treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases AT cassanonicoletta treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases AT venaginoantonio treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases AT demarcoaurora treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases AT cazzatogerardo treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases AT mennunibiaginagisella treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases |